DV
Dividend Vision

IRD — Opus Genetics, Inc.

Opus Genetics, Inc. (IRD)

Its deepest 1-year drawdown was 49.2%.

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company developing gene therapies to treat inherited retinal diseases and other ophthalmic disorders, with programs including OPGx-LCA5 and OPGx-BEST1 in clinical trials and multiple candidates in pre-clinical development, along with small-molecule therapies for conditions such as diabetic retinopathy and presbyopia. The company does not currently distribute dividends. This security appeals to investors seeking exposure to early-stage biotechnology with a focus on rare genetic eye diseases, though it carries the typical risks associated with clinical-stage pharmaceutical development.

IRD key facts

Asset type
Stock
Asset class
Equity
Inception date
11/30/2004
Last close
$3.61
Market cap
$251,825,776
Average volume
414200.0
Payment date
11/06/2020
Beta
0.555
Payout ratio
0.0
Forward P/E
12.0048
EPS
$-1.22